Singaporean biotechnology startup Automera secures $16 million in series A funding. Jointly led by Accelerator Life Science Partners (ALSP) and ClavystBio, the round witnessed participation from EDBI, Xora Innovation, and other undisclosed investors. Automera plans to use the fresh funds to deploy its autophagy-targeting chimera small molecules (AUTAC) platform toward the development of potentially transformative therapies.
_
This article has been summarised for a quick read. You can find the original article on Tech in Asia.